Physician profile
Patrick J Cook
NPI 1427035450
$6,385.02
in general payments reported to CMS, 2019-2025
30 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $563 · 2021: $819 · 2022: $540 · 2023: $1,037 · 2024: $1,310 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,446.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,219.19 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $881.72 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $846.94 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $750.58 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $500.96 | 2022-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals Lp | $435.13 | 2019-2025 | Farxiga, Wainua |
| Pfizer INC. | $263.44 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $223.70 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.44 | 2023-2025 | Jardiance |
| Atricure, INC. | $158.63 | 2021 | |
| Novo Nordisk INC | $98.49 | 2024-2025 | Wegovy |
| Bridgebio Pharma, INC. | $94.91 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $86.88 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $82.37 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $66.72 | 2023-2024 | Inpefa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $55.37 | 2025 | |
| Amarin Pharma, INC. | $53.06 | 2019 | |
| Cvrx, INC. | $51.02 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $41.69 | 2019-2022 | |
| Astellas Pharma US INC | $38.93 | 2019 | |
| Arbor Pharmaceuticals, INC. | $38.81 | 2021 | |
| Esperion Therapeutics, INC. | $33.99 | 2024 | Nexletol |
| Abiomed | $32.27 | 2024 | Impella |
| Heartflow, INC. | $31.25 | 2022 | |
| Cleerly, INC. | $24.32 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Takeda Pharmaceuticals U.S.A., INC. | $21.46 | 2019 | |
| Shire North American Group INC | $16.78 | 2019 | |
| Medtronic, INC. | $13.56 | 2022 | |
| Mannkind Corporation | $12.01 | 2020 | |
| Companion Medical, INC. | $10.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.